SARS-CoV-2 Acute Respiratory Disease
43
1
2
25
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.7%
2 terminated out of 43 trials
92.6%
+6.1% vs benchmark
7%
3 trials in Phase 3/4
16%
4 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (43)
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
SARS-COV-2 Screening in Dialysis Facilities
Follow-up of Covid-19 Long Term Sequelae
Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
A Retrospective Study of COVID-19 Treatments
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2
About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
NAC for Attenuation of COVID-19 Symptomatology
Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor